A
ArriVent BioPharma, Inc. (AVBP)
NGM – Real Time Price. Currency in USD
34.00
+0.17 (0.52%)
At close: Jun 26, 2026, 4:00 PM EDT
34.00
-0.00 (-0.00%)
After-hours: Jun 26, 2026, 4:36 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
34.00
+0.17 (0.52%)
At close: Jun 26, 2026, 4:00 PM EDT
34.00
-0.00 (-0.00%)
After-hours: Jun 26, 2026, 4:36 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $62.1M significantly exceed its total debt $419.0K, ensuring strong financial flexibility
Total current assets $348.7M exceed Total current liabilities $25.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$41.9M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 13.95 | 6.05 | 10 | |
| Quick ratio | 13.95 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -37M | -75M | -94M | -178M | -157M |
| Net Income | -37M | -69M | -80M | -166M | -145M |
| EBITDA | -37M | -75M | -94M | -178M | -157M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -9.73 | 1.0 |
| Next quarter | N/A | -21.74 | 1.0 |
| Current year | N/A | 6.34 | 3.0 |
| Next year | N/A | 14.88 | 4.5 |
| Weighted average score | 2.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -21.87 | -14.32 | -36.63 | 3.3 |
| Y/Y | 999 | 32.72 | 49.47 | 38.4 | 10 |
| 3y average | 999 | -70.17 | 11.68 | -60.79 | 4.8 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 4.8 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |